Omeros Corp. Stock
Omeros Corp. Stock
A very strong showing by Omeros Corp. today, with an increase of €0.65 (6.370%) compared to yesterday's price.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
Based on the current price of 10.85 € the target price of 30 € shows a potential of 176.5% for Omeros Corp. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Omeros Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.
Pros and Cons of Omeros Corp. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | 6.370% | 15.385% | 26.551% | 227.553% | -24.444% | 185.554% | -17.841% |
| Evolus Inc | -0.880% | -7.848% | -16.214% | -35.039% | -8.220% | -44.729% | -46.787% |
| Heron Therapeutics Inc. | -1.530% | 6.405% | 19.806% | -69.444% | -60.036% | -70.121% | -95.572% |
| Rhythm Pharmaceuticals | -1.680% | -8.556% | -13.198% | 14.765% | -8.556% | 292.202% | 519.565% |
Comments
Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (OMER) had its price target lowered by HC Wainwright from $40.00 to $33.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (OMER) had its "buy" rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
News
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Choosing between Heartflow (NASDAQ:HTFL) and Omeros (NASDAQ:OMER) in 2026 requires balancing the rapid revenue growth of an AI diagnostic platform against the high-stakes commercial launch of a new
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique
Omeros Q1 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA
